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Background: Patient awareness of COPD refers to knowledge and acceptance of the disease 
and its treatment. Although it is relevant to management and outcomes, the disease awareness 
of patients is poorly investigated, and no validated questionnaires are currently available. 
We aimed to develop the novel Disease Awareness in COPD Questionnaire (DACQ), which 
was validated in relation to demographic and clinical features, in patients participating in the 
SATisfaction and Adherence to COPD Treatment (SAT) study.
Methods: DACQ was developed according to a list of items regarding the patient’s knowledge, 
acceptance, and perception of COPD as well as of treatment needs. The questionnaire was vali-
dated by assessing internal structure and consistency, correlations with other patient-reported 
outcomes, and stability over time. Furthermore, the extent of disease awareness of patients 
enrolled in the SAT study was assessed by using DACQ, and correlations with demographic 
and clinical features were evaluated.
Results: DACQ was composed of four domains. Overall reliability and stability over time 
were adequate; correlations between DACQ and other tools measuring different constructs 
(ie, treatment satisfaction, illness perception, impact of COPD symptoms on daily life, and 
dyspnea severity) were, as expected, more limited. In the enrolled patient sample, a suboptimal 
level of disease awareness (,70%) was detected, especially in terms of disease acceptance and 
perception. Disease knowledge was positively associated with COPD severity, while the impact 
of symptoms on daily life was negatively associated with disease acceptance, awareness of 
treatment needs, and overall awareness.
Conclusion: DACQ proved to be a reliable tool to assess awareness in COPD patients. Aware-
ness of COPD patients need to be improved.
Clinical trial registration: ClinicalTrials.gov ID# NCT02689492.
Keywords: COPD, awareness, questionnaire, patient satisfaction
Plain language summary
The more patients with COPD are aware of the disease, treatment, and management, the more 
likely is their engagement, resulting in a better COPD care. Although relevant to disease man-
agement and outcome, disease awareness is poorly investigated, and no validated questionnaires 
considering all its domains are currently available to measure its extent.
We developed the Disease Awareness in COPD Questionnaire (DACQ), which was validated 
in the patients with COPD enrolled in the observational, multicentre, prospective “SATisfaction 
and Adherence to COPD Treatment” (SAT) study.
The validated DACQ proved to be a reliable patient-reported outcome tool for measuring 
the complex and multifaceted disease awareness of patients with COPD.
A well-known problem in COPD management is the low rate of adherence to long-term treat-
ment. Assessment and reinforcement of awareness may be helpful for improving this issue.
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Introduction
COPD is the third leading cause of death worldwide1 and a 
cause of patients’ disability.2,3 Disease awareness has been 
defined as understanding the disease and being conscious 
of it, its prognosis, and associated life expectations, as 
originated from the personal rework of information with 
which the patient has been provided.4 While patient educa-
tion is essential for a successful management of a disorder, 
the concept of awareness can be extended beyond mere 
information and knowledge on the diagnosis and features of 
the disease. It should include all domains establishing a full 
awareness of the disease, its consequences, and the burden 
of the condition, as well as the understanding of the need for 
a therapeutic regimen. Programs mainly aimed at updating 
knowledge, according to the GOLD,5 and at enhancing the 
consciousness of COPD, its management, and importance 
as a public health problem and are being implemented in 
several countries.6 The National Heart, Lung, and Blood 
Institute has taken several initiatives since 2007 to raise the 
awareness of patients and their families in relation to specific 
health topics, including asthma7 and COPD8 in cooperation 
with leading professional societies, health organizations, and 
advocacy groups.9,10 Unsatisfying adherence to treatment is 
a well-known problem in COPD management, despite the 
huge disease burden. Indeed, at least half of patients receiving 
long-term pharmacotherapy do not adhere to treatment.11–14
The more patients are aware of the disease, treatment, and 
management, the more likely is their active collaboration, 
resulting in better COPD care. Therefore, further efforts are 
needed to investigate all components of disease awareness 
and to develop targeted training and suitable educational 
initiatives.
Literature data on awareness of COPD are still poor and 
limited only to some components of the paradigm, such as 
patient’s information, beliefs, perceptions, and perspectives 
on treatments.15 The level of knowledge and understand-
ing about the disease have been explored in the general 
population,15,37 in current smokers,10,38 and in COPD patients9 
by means of surveys or unvalidated questionnaires. Unfortu-
nately, no validated tools are currently available for measur-
ing different dimensions of patients’ COPD awareness.
The aim of this study was to develop and validate the 
novel Disease Awareness in COPD Questionnaire (DACQ) 
in patients participating in the SATisfaction and adherence 
to COPD treatment (SAT) study (SAT; ClinicalTrials.gov 
ID# NCT02689492). The purpose was to obtain a short, 
simple, and user-friendly tool that can be used both in 
research and in clinical practice. The extent of patients’ 
COPD awareness was assessed by using the DACQ tool, and 
its correlations with disease features and patients’ outcomes 
were examined.
Methods
SaT study design
The SAT study patients were required to be $40 years of 
age, receiving stable pharmacological COPD treatment, and 
have had no exacerbations for at least 3 months. They were 
enrolled in 20 Italian pulmonological centers and followed 
up to 12 months. Follow-up visits occurred every 6 months 
(with 1 month of tolerance). The SAT observational study 
was conducted in accordance with the amended Declaration 
of Helsinki. The University of Genoa Ethic Committee 
(Protocol N°: 343REG2015) approved the study protocol, 
and written informed consent was obtained from all patients. 
The institutional ethics committees involved in the study are 
listed in Table S1. No individual data will be shared. Further 
data will be published with main clinical trial results and other 
subanalysis (eg, pharmacoeconomic data); the data will be 
shared through open access manuscripts.
At the enrollment visit and at 6-month follow-up, patients 
were administered the list of items approved by the Steering 
Committee along with the Brief-Illness Perception Ques-
tionnaire (B-IPQ),16 the COPD Assessment Test (CAT),17 
the Treatment Satisfaction Questionnaire for Medication 
(TSQM-9),18,19 and the modified Medical Research Council 
(mMRC) dyspnea scale.20
DaCQ development and validation
A list of 38 items exploring patient’s knowledge, accep-
tance, and perception of COPD and awareness of treatment 
needs was generated by physicians and experts in health 
psychology, based on patients’ input and literature search. 
Applying two rounds of the Delphi method,21 the SAT study 
Steering Committee members identified the most relevant 
items to characterize COPD awareness, suggested additional 
items, and rephrased the existing ones, if appropriate.
At study inclusion, SAT study patients were asked to 
complete the questionnaire with the selected items. The 
DACQ total and domain scores were computed as the sum 
of nonmissing items, after having assigned the appropriate 
score to each item in such a way that higher scores reflected 
a higher grade of awareness. Scores were normalized to a 
scale ranging from 0 to 100.
An exploratory factor analysis was conducted to identify 
potential domains, while Rasch models for polytomous 
items22–26 were used (according to the Item Response Theory 
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approach) to evaluate the scalability of items and to test 
whether patients used the items response scale correctly.27,28 
For the Rasch analysis, information-weighted (INFIT) 
and outlier-sensitive (OUTFIT) indices were considered. 
Moreover, item-person maps, which provide both the 
person measures and the item measures on the same linear 
(logit) scale, were plotted to determine how items were 
suited to the patient’s ability. Items with absolute factor 
loadings ,0.3 in the factor analysis, or not fitting the Rasch 
model, were removed.
The scale homogeneity was evaluated by means of 
the Cronbach’s coefficient α. Less correlated items were 
removed, and the analysis was repeated until an acceptable 
level of reliability (α$0.70) was achieved.29,30
Internal consistency, construct validity, and stability after 
6 months were evaluated as psychometric characteristics of 
the final DACQ by means of Cronbach’s α, Spearman cor-
relation coefficient ρ
S
 with other questionnaires and scales 
used in the study and intraclass correlation coefficient,31 
respectively.
Disease awareness extent
The levels of awareness, as well as the distribution of the 
DACQ total and domain scores with respect to the demo-
graphic and clinical characteristics, were evaluated at 
study entry.
Two-sample t-test and ANOVA (or respective analogous 
nonparametric tests, if appropriate) were used to evaluate 
the statistical significance of differences in scores among 
different groups of patients. Moreover, the associations 
between awareness and patient age, gender, COPD severity 
(based on the GOLD 2017 risk categories),5 and impact of 
symptoms (by means of the CAT score) were investigated 
with a multivariable linear regression analysis.
Analyses were performed using SAS 9.4, SPSS v. 20.0, 
and WINSTEPS 3.72.3. Statistical analyses, project man-
agement, and quality control were performed by MediNeos 
Observational Research (Modena, Italy).
Results
DaCQ development and validation
Starting from the initial list of items, the Delphi method led 
to a provisional questionnaire of 27 items. Patients enrolled 
in the SAT study were administered the 27-item question-
naire; subject demographic and clinical characteristics are 
reported in Table 1. At the enrollment visit, the frequency 
of missing answers to each item was ,3%, which is below 
the 5% recommended threshold.32 Therefore, the issue of 
missing data was not further dealt with.
Factor and Rasch analyses were conducted on the 347 
structured questionnaires that were completed by patients at 
study entry. Four distinct latent factors with eigenvalues .1 
were extracted: items 7, 15, 16, 22, 24, and 25 were allo-
cated to the first factor; items 3, 4, 9, 12, 14, 17, 18, and 23 
to the second one; items 1, 2, 19, and 26 to the third one; 
and items 5, 8, 10, 11, 13, 20, 21, and 27 to the fourth one 
(Table S2). On the basis of the question text of the items 
that such factors were composed of, it was deduced that 
these four domains assess the patients’ Disease acceptance, 
Awareness of treatment needs, Disease knowledge, and 
Disease perception, respectively. Therefore, COPD aware-
ness was conceptualized as a composite, aggregate con-
struct of these four domains,39 meaning that such domains 
combine to produce the latent construct. Moreover, on the 
basis of the factor analysis results (Table S2), only item 20 
(assigned to the fourth factor) might have been allocated 
to other domains. We did not identify evidence of other 
possible relevant overlap among the four extracted factors. 
Table 1 Demographic and clinical characteristics of patients at 
the enrollment visit
Total number of patients 401
age (years); mean ± SD 71.7±7.6
Gender, n (%)  
Males 299 (74.6)
Females 102 (25.4)
Smoking habits, n (%)  
nonsmokers 21 (5.2)
Former smokers 282 (70.3)
Current smokers 98 (24.5)
Highest education level, n (%)a  
none 6 (1.9)
Primary school 138 (42.7)
Middle school 105 (32.5)
High school 51 (15.8)
academic degree 23 (7.1)
COPD duration (years); median  
(25th–75th percentile) (n=401)
4.9 (2.1–9.2)
CaT score; mean ± SD (n=401) 15.7±7.8
CaT score group, n (%)  
CaT ,10 96 (23.9)
CaT $10 305 (76.1)
COPD GOlD 2017 grade, n (%)a  
Grade a 70 (19.1)
Grade B 254 (69.4)
Grade C 2 (0.6)
Grade D 40 (10.9)
FeV1 predicted (%); mean ± SD (n=369) 64.7±28.7
Note: aPatients with missing information were not considered.
Abbreviations: CaT, COPD assessment Test; FeV1, forced expiratory volume 
in one second.
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This also supports the aggregate structure of the DACQ 
latent construct.
The item location and the fit statistics resulting from the 
Rasch analysis are reported in Table S3: all the INFIT and 
OUTFIT values were satisfactory, with the only exceptions 
being items 6 and 25.
According to the findings of factor and Rasch analyses, 
and based on the clinical interpretation of preliminary results 
as well, five items (3, 6, 11, 16, and 17) were removed, result-
ing in a 22-item version of the questionnaire.
To evaluate the shortened scale homogeneity, 339 patients 
at enrollment also completed the B-IPQ, mMRC, TSQM-9, 
and CAT questionnaires and scales and were considered. 
At first, the overall evaluation of the 22-item questionnaire 
resulted in a Cronbach’s α coefficient of 0.69. The removal 
of the least correlated items (ie, items 13 and 27, which also 
showed a nonsatisfactory performance in the factor and Rasch 
model analyses) led to an overall α=0.72.
No further selection of the items was deemed to be neces-
sary, leading to a final pool of 20 items (Table 2). The English 
translation of selected items (not linguistically validated) is 
reported in Table 2 only for informative purposes.
Both the global DACQ and its four domains showed 
an acceptable-to-good internal consistency (Cronbach’s α 
coefficients were 0.81 for disease acceptance, 0.73 for aware-
ness of treatment needs, 0.70 for disease knowledge, and 
0.56 for disease perception). Regarding construct validity, 
the correlation coefficients between the DACQ score and 
the TSQM-9 global satisfaction score (ρ
S
=0.40), B-IPQ 
(ρ
S
=-0.40), CAT (ρ
S
=-0.29), and mMRC (ρ
S
=-0.19) were 
calculated (all P#0.0001). All correlations were in the 
expected direction, but the magnitude of association was 
limited, meaning that, as expected, the DACQ construct is 
correlated with but different from those measured by the other 
considered patient-reported outcomes (PROs; ie, treatment 
satisfaction, illness perception, impact of COPD symptoms 
on daily life, and dyspnea grade).
The stability over time of the DACQ was evaluated after 
6 months on 79 patients with stable disease (CAT score 
variation 1 point). Almost all items showed a moderate-
to-good stability,33 with intraclass correlation coefficient 
values ranging from 0.33 to 0.64 (Table S4). The stability 
of the DACQ total and domains scores was satisfactory 
(ρ
S
=0.65 for disease acceptance, ρ
S
=0.60 for awareness of 
Table 2 Structure of the Disease awareness in COPD Questionnaire (DaCQ)
Item # Item text Domain
01 I need to be treated with inhaled drugs forever Disease knowledge
02 I believe that COPD tends to worsen over time Disease knowledge
04 a regular administration of drugs allows me to move with less effort awareness of treatment needs
05 I think that COPD is a mild disease since it is treated with inhaled drugs Disease perception
07 I cannot easily accept to have COPD Disease acceptance
08 Inhaled drugs are less effective than pills, tablets, or other oral medications Disease perception
09 Treatments for COPD must be taken regularly awareness of treatment needs
10 I prefer to ignore COPD symptoms Disease perception
12 a regular therapy reduces the risk of sudden worsening awareness of treatment needs
14 Inhaled drugs help improving the fatigue in breathing awareness of treatment needs
15 I am worried about my COPD Disease acceptance
18 Spirometry is a fundamental examination for the COPD diagnosis awareness of treatment needs
19 I will never heal from my COPD Disease knowledge
20 I think I will never heal from my COPD because there is lack of effective drugs Disease perception
21 I prefer not to think about my COPD Disease perception
22 I am angry because of my COPD Disease acceptance
23 Drugs for COPD improve my symptoms awareness of treatment needs
24 I am having difficulty living with COPD symptoms Disease acceptance
25 I wonder why COPD happened to me Disease acceptance
26 COPD is a chronic disease and it is not possible to heal from it Disease knowledge
Notes: Final list of the 20 selected items and of the respective domains. Seven items that were removed during the selection process are not shown. The questionnaire 
with the indicated items was administered to patients in their original, Italian version. The english translation provided in the table was not linguistically validated, and it is 
shown only for informative purpose. Items #03, #06, #11, #13, #16, #17, and # 27 were removed from the final DACQ, based on the results of the validation statistical 
tests performed.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
93
.5
8.
20
6.
19
1 
on
 1
7-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2019:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5
evaluation of COPD awareness
treatment needs, ρ
S
=0.61 for disease knowledge, ρ
S
=0.38 
for disease perception, and ρ
S
=0.54 for DACQ total score; 
all P,0.001).
Disease awareness extent
The following results were obtained considering the patients’ 
answers to the 20 items of the DACQ.
The mean level of awareness (normalized DACQ total 
score) was 69 (SD=11, N=367; Figure 1). No significant 
differences in DACQ total or domain scores were found 
between younger and older patients or between males and 
females (Tables S5 and S6). On the contrary, significant 
differences were identified among COPD severity groups5 
in terms of disease acceptance (P,0.0001), disease 
knowledge (P=0.0007), and DACQ total score (P=0.0084; 
see Table S7 and Figure 2). Notably, significant differ-
ences were also found between patients with CAT $10 
vs CAT ,10 for disease acceptance (P,0.0001), aware-
ness of treatment needs (P=0.0453), disease knowledge 
(P=0.0005), and DACQ total score (P=0.0004; see Table S8 
and Figure 3).
The association between patients’ awareness and their 
main demographic and clinical characteristics was investi-
gated (Table 3). Consistent with the above-reported results, 
the CAT score negatively affected disease acceptance 
(β=-1.2944, P,0.0001), awareness of treatment needs 
(β=-0.4539, P=0.0003), and DACQ total score (β=-0.4242, 
P,0.0001). However, there was no association with disease 
knowledge.
Discussion
The extent of patients’ COPD awareness has been poorly 
investigated thus far. Despite the ongoing gainful efforts 
to increase COPD awareness,8 further actions are definitely 
needed to evaluate all domains involved and to launch appro-
priately tailored interventions.
During the SAT observational study, the DACQ was 
generated and tested following well-established procedures. 
The DACQ provides both a total score (indicating the global 
level of awareness) and specific scores about: 1) disease 
knowledge (the mastery of a correct knowledge on COPD 
characteristics), 2) awareness of treatment needs (the level 
of subjective view on necessity and role of COPD therapy), 
3) disease perception (how the patient perceives COPD in 
terms of features and consequences), and 4) disease accep-
tance (the individual acceptance of thoughts and feelings 
related to COPD).
DACQ proved to be easily understandable by patients and 
showed good reliability in terms of internal consistency, ade-
quate construct validity, and moderate-to-good stability over 
time, making it suitable for the application. In the absence 
of a “gold standard” to evaluate awareness, we assessed the 
level of convergence of DACQ with the PROs. Convergent 
validity is generally considered adequate if the correlations 
with an instrument measuring the same construct is .0.50.40 
However, as recently proposed,41 if comparator constructs are 
only vaguely related to the construct under study, more flex-
ibility in interpreting the correlation magnitude is allowed. 
The TSQM-9 and B-IPQ (evaluating treatment satisfaction 
Figure 1 Patients’ COPD awareness at enrollment.
Notes: normalized DaCQ scores (range 0–100) of COPD patients at enrollment visit; higher scores represent higher levels of awareness; mean values (bars), 1 SD (whiskers).
Abbreviation: DaCQ, Disease awareness in COPD Questionnaire.
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and threatening views of diseases, respectively) were mod-
erately correlated with awareness (DACQ total score), since 
they do not assess the same construct of DACQ. The correla-
tion with CAT and mMRC was even lower, confirming the 
divergent validity. Good reliability in terms of internal con-
sistency was achieved for all the domains, except for disease 
perception, which showed a Cronbach’s α slightly below the 
acceptable threshold. This is probably due to the fact that the 
“disease perception” domain comprised the items showing 
lower factor loadings in the factor analysis. However, we 
decided not to remove them because we believed that they 
reinforce the overall assessment of the DAC construct.
In the patients referring to pulmonology centers and 
enrolled in the SAT study, the level of COPD awareness was 
Figure 2 Patients’ COPD awareness according to GOlD 2017 disease severity grades.
Notes: normalized DaCQ scores (range 0–100) for: (A) disease acceptance, (B) awareness of treatment needs, (C) disease knowledge, and (D) disease perception; median 
values (numbers), bottom and top of each box are the 25th and the 75th percentiles, respectively; bottom end and top end of the whiskers are minimum and maximum of 
all data, respectively. (E) normalized DaCQ total score; mean values (bars), 1 SD (whiskers). Higher scores represent higher levels of awareness. asterisk (*) indicates a 
statistically significant difference (P,0.05); the number of patients (N) in each GOLD 2017 grade group is indicated. Only two patients were classified as GOLD 2017 C grade; 
therefore, they were excluded from the analysis because of the insufficient sample size.
Abbreviation: DaCQ, Disease awareness in COPD Questionnaire.
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suboptimal. Disease acceptance was particularly poor on aver-
age, while awareness of treatment needs and disease knowledge 
were higher. COPD awareness was not associated with either 
patients’ age or gender. Disease awareness was lower in patients 
with a higher extent of symptoms in daily life. However, 
patients with a higher CAT score also had lower acceptance 
and consciousness of treatment needs, both of which are key 
components of awareness. This may explain why they had a 
limited global awareness compared with patients with lower 
CAT score. Therefore, the higher is the impact of symptoms, 
the lower is the acceptance of the disease and the greater neces-
sity of therapy. This aspect could be due to patients’ doubts 
about treatment efficacy since the pharmacological treatments 
for COPD neither cure nor provide immediate relief.
Patients with more severe COPD (GOLD grade D) are 
more likely to experience worsening COPD. This implies 
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Figure 3 Patients’ COPD awareness according to baseline CaT score.
Notes: normalized DaCQ scores (range 0–100) for: (A) disease acceptance, (B) awareness of treatment needs, (C) disease knowledge, and (D) disease perception; median 
values (numbers), bottom and top of each box are the 25th and the 75th percentiles, respectively; bottom end and top end of the whiskers are minimum and maximum of 
all data, respectively. (E) Normalized DACQ total score; mean values (bars), 1 SD (whiskers). Higher scores represent higher levels of awareness. Statistically significant 
differences: *P,0.05; **P,0.01; the number of patients (n) in each CaT group is indicated.
Abbreviations: CaT, COPD assessment Test; DaCQ, Disease awareness in COPD Questionnaire.
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that such patients should be more aware of their chronic 
condition and their need for life-lasting COPD treatments. 
Consistently, we found that disease knowledge was positively 
associated with COPD severity. In particular, grade D patients 
showed stronger background knowledge of their condition 
compared with grade A patients. Hence, the more severe the 
disease, the more informed are the patients. The possibility of 
evaluating the different components of awareness allows for 
the detection of the specific needs of each group of patients 
and for planning personalized strategies and interventions.
These study findings highlight that the patients’ knowl-
edge about COPD is quite satisfactory, while their acceptance 
and perception of the disease need to be enhanced. Targeted 
education programs, as well as a more effective communica-
tion between health care providers and patients, are desirable 
to improve patients’ understanding and attitude to cope with 
their condition.
Our study was conducted in a real-life setting using the 
COPD severity staging according to GOLD 2017 recom-
mendations, which is based on symptoms and history of 
exacerbations exclusively in which a large variability of 
severity staging at the individual patient level is proved.42 
Most patients were classified as grade B (ie, with a lower 
risk of exacerbations but with a higher impact of COPD 
on their lives). Grade A, C, and D patients accounted for 
only ~31% of the sample. Similarly, subjects with CAT ,10 
(ie, lower impact of symptoms) were approximately one-
fourth of the sample. However, in this observational study, 
no selection methods were implemented to examine more 
balanced groups of patients according to the investigated 
clinical characteristics because our aim was to survey a rep-
resentative sample of the patients managed in the real-life 
specialist respiratory setting. Nevertheless, further studies in 
other settings, and with a different distribution of patients’ 
severity and symptoms, would be useful to further explore 
our study findings.
Previous studies developed different kinds of surveys 
somehow related to awareness in patients with COPD by 
means of tools that did not undergo a proper validation 
process. A population-based questionnaire with 85% sen-
sitivity and 45% specificity has been proposed as a screen-
ing tool for persons unaware of risk factors for COPD.34 
An Internet-based survey focused on the perception of the 
disease and its exacerbations in a real-world population of 
patients with COPD, resulting in most patients being worried 
about long-term health and premature death.35 A national 
public survey with a structured questionnaire evaluated the 
perception of a large Italian population with obstructive lung 
diseases, highlighting the need for interventions to improve 
the awareness of these disorders and of COPD in particular.15 
In the clinical setting, an Indian survey36 and a Korean study10 
used different COPD awareness questionnaires and obtained 
similar results, indicating the urgent need for educating the 
public to increase the awareness of patient with COPD for the 
improvement of their self-management and quality of life.
Beyond these interesting results, the DACQ tool pre-
sented here is unique because it analyses different domains 
composing COPD awareness that may allow the patients 
to reach both knowledge and acceptance of the disease and 
its treatment. Therefore, the results of this study indicate 
that DACQ may represent a valid tool for further insights 
on DACQ.
Conclusion
The validated DACQ proved to be a reliable PRO instrument 
for measuring a complex, multifaceted construct such as 
Table 3 Multivariable linear regression analysis: association between COPD awareness and baseline demographic/clinical characteristics 
of the patients
Age Gender  
(female vs male)
CAT score COPD severity 
(grade B vs grade A)
COPD severity 
(grade D vs grade A)
Disease acceptance β=0.1062
P=0.5402
β=-1.0278
P=0.7269
β=-1.2944
P,0.0001
β=-0.1942
P=0.9613
β=-11.1581
P=0.0601
awareness of 
treatment needs
β=-0.0077
P=0.9383
β=1.8417
P=0.2800
β=-0.4539
P=0.0003
β=2.5184
P=0.2774
β=6.5718
P=0.0555
Disease knowledge β=-0.0939
P=0.5020
β=1.1211
P=0.6378
β=0.1801
P=0.2988
β=6.2181
P=0.0533
β=10.2216
P=0.0316
Disease perception β=-0.0228
P=0.8654
β=0.7215
P=0.7499
β=-0.0170
P=0.9186
β=-1.7595
P=0.5709
β=-0.2070
P=0.9635
DaCQ total score β=-0.0017
P=0.9837
β=0.5367
P=0.6986
β=-0.4242
P,0.0001
β=0.5152
P=0.7850
β=0.0712
P=0.9795
Notes: Only two patients were classified as GOLD 2017 C grade; therefore, they were excluded from the analysis because of the limited group size. A higher CAT score 
represents a greater impact of symptoms in patient’s daily life. Statistically significant results are highlighted in bold.
Abbreviations: CaT, COPD assessment Test; DaCQ, Disease awareness in COPD Questionnaire.
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disease awareness of COPD patients and it is easy to com-
plete and score. This tool was developed during the SAT 
observational study in a real-life clinical setting. The results 
of this study showed an incomplete awareness of patients 
cared for in a specialist setting and provided the basic data 
for developing strategies to improve the diseases awareness 
in COPD patients.
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